Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22147344 | 0.83 | ALDH1A1 (0.44) | NPC1RAB9ALMNATP53MAPT | |
| SCHEMBL5782311 | 0.79 | NPC1 (0.41) | IKBKBNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL4908635 | 0.77 | RAB9A (0.43) | IKBKBNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL4906065 | 0.77 | IKBKB (0.41) | IKBKBNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL20464263 | 0.73 | LMNA (0.30) | LMNA | |
| SCHEMBL4902841 | 0.72 | MAPT (0.47) | KDM4ELMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL28540545 | 0.71 | NPC1 (0.44) | IKBKBNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL5901217 | 0.70 | PPARG (0.45) | RAB9ANOTUMLMNAS1PR1 | |
| SCHEMBL2868912 | 0.69 | ALDH1A1 (0.50) | IKBKBNOTUMNR1H4 | |
| SCHEMBL17047950 | 0.69 | ALDH1A1 (0.42) | NPC1RAB9AKDM4ELMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | IKBKB 1050/4885NPC1 1346/4885RAB9A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.